

DRUGS OF CURRENT INTEREST (DOCI) LIST - October 2000

The purpose of the Drugs of Current Interest (DOCI) List is to stimulate reporting for a selected group of marketed drugs in order to identify drug safety signals. The maintenance of this list by the Canadian Adverse Drug Reaction Monitoring Program facilitates regular monitoring and constitutes one element of post-approval assessment activities. The following criteria are considered for inclusion of drugs on the DOCI list:

- < recently marketed drugs (<2 years), with limited post-marketing experience and potential safety concern from pre-market review;
- < marketed drugs for which there are emerging safety concerns, new serious adverse drug reactions that are unlabelled in the product monograph (e.g., safety signals observed internationally);
- < the first marketed drug of a new pharmacological or chemical class of medication.

abacavir (Ziagen™)
alteplase (Activase® rt-PA)
bupropion (Zyban®, Wellbutrin SR®)
celecoxib (Celebrex™)
clopidogrel (Plavix™)
delavirdine (Rescriptor™)
factor VII - recombinant, activated (NiaStase™)
Hypericum perforatum (St. John's Wort)
indinavir (Crixivan®)
mefloquine (Lariam®)
naratriptan (Amerge®)
nevirapine (Viramune®)

oseltamivir (Tamiflu™)
ritonavir (Norvir®)
rituximab (Rituxan®)
rofecoxib (Vioxx™)
rosiglitazone (Avandia®)
saquinavir (Invirase™)
sildenafil (Viagra™)
terbinafine (Lamisil®)
trastuzumab (Herceptin®)
trovofloxacin (Trovan™)
zanamivir (Relenza™)
zolmitriptan (Zomig®)

Également disponible en français sous le titre *Liste des médicaments d'intérêt courant (MIC)*.

October 2000

©Minister of Public Works and Government Services Canada, 2000